Immunocore Holdings AI Stock Analysis
Immunocore Holdings (6YG) AI Stock Analysis
Immunocore Holdings
(Frankfurt:6YG)
No summary available
Immunocore Holdings (6YG) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 1.57B
- Dividend Yield
- ―
- Average Volume (3M)
- 85
- Price to Earnings (P/E)
- -48.0
- Beta (1Y)
- 0.39
- Revenue Growth
- 7.68%
- EPS Growth
- ―
- Country
- Germany
- Employees
- 524
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Immunocore Holdings Business Overview & Revenue Model
Company Description
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of ser...
Immunocore Holdings Earnings Call Summary
The call was strongly positive, supported by 16% first-half KIMMTRAK revenue growth, 18% second-quarter growth, landmark five-year survival data, improving net losses, a strong cash position, and progress across three phase III melanoma trials and multiple early-stage programs. The main challenges were moderating underlying sequential growth, a Q3 inventory-related headwind, higher second-half rebate payments, and continued unmet need and exploratory-stage development in certain indications.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Immunocore expects moderating growth for KIMMTRAK, with underlying quarterly sequential growth of 3%; R&D expenses are expected to modestly increase year-over-year, although at a slower rate than in 2025; sales-related rebates are expected to be approximately $120 million during the second half of this year and return in 2027 to similar amounts as paid in 2025, which was in the $65 million-$70 million range; TEBE-AM enrollment is nearing the target of 540 patients, with top-line data still expected as early as the end of this year, while TEBE-AM headline data could be as early as the end of 2026; PRISM-MEL-301 enrollment completion is targeted by late 2027; updated PRAME data are expected by the end of the year, initial preproinsulin data in 2027, the first Type 1 diabetes patient is expected to be dosed in the coming weeks, the CTA for the second autoimmune candidate is expected by the end of 2026, and HIV data are planned for the first half of 2027.
Immunocore Holdings Risk Analysis
Immunocore Holdings disclosed 103 risk factors in its most recent earnings report. Immunocore Holdings reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksImmunocore Holdings Peers Comparison
Overall Rating
ZYME69Neutral
XNCR54Neutral
CTMX47Neutral
IMTX46Neutral
JANX42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ZYME | 69Neutral | $2.02B | 39.95 | 22.48% | ― | 97.78% | ― |
| XNCR | 54Neutral | $3.00B | -24.53 | -21.29% | ― | 33.55% | 11.51% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CTMX | 47Neutral | $464.35M | -4.55 | -33.97% | ― | -87.66% | -210.45% |
| IMTX | 46Neutral | $1.00B | -3.46 | -52.19% | ― | -44.50% | -80.18% |
| JANX | 42Neutral | $758.06M | -7.18 | -10.68% | ― | 132.89% | 4.85% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:6YG | Immunocore Holdings Plc | 28.20 | -2.60 | -8.44% | |
| XNCR | Xencor Inc. | 38.13 | 23.20 | 155.39% | |
| CTMX | CytomX Therapeutics Inc. | 2.04 | -1.84 | -47.42% | |
| ZYME | Zymeworks | 26.47 | 7.95 | 42.93% | |
| IMTX | Immatics N.V. | 6.52 | -3.68 | -36.08% | |
| JANX | Janux Therapeutics, Inc. | 11.49 | -17.79 | -60.74% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.